Immunomodulation by α(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human α(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes

INTRODUCTION: Recombinant α(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with α(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosheimer, Birgit, Alzner, Reinhard, Wiedermann, Christian J.
Formato: Texto
Lenguaje:English
Publicado: Birkhäuser-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766450/
https://www.ncbi.nlm.nih.gov/pubmed/18060368
http://dx.doi.org/10.1007/s00005-007-0045-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766450/
https://www.ncbi.nlm.nih.gov/pubmed/18060368
http://dx.doi.org/10.1007/s00005-007-0045-3

Ejemplares similares